Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this year.

JointMedica, a global leader in orthopedic innovation, announces the commencement of an Investigational Device Exemption (IDE) study for its Polymotion® Hip Resurfacing (PHR®) device. The IDE study ...

The intravascular lithotripsy market has undergone high growth trailblazed by J&J subsidiary Shockwave Medical.

Full REMAIN-1 pivotal study enrollment anticipated in summer 2025 ...

Transformational 2024: successfully advanced from preclinical to clinical stage companyStrengthened leadership team to drive growth and advance ...

MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, ...

In 2024, ONWARD added 20 patents to its IP portfolio. It now has more than 150 issued patents, excluding EP country ...

Abbott (ABT) announced that the U.S. Food and Drug Administration, FDA, has approved an investigational device exemption, IDE, for its Coronary ...

Abbott begins new Intravascular Lithotripsy trial to improve outcomes in patients with coronary artery disease: Abbott Park, Illinois Wednesday, March 26, 2025, 15:00 Hrs [IST] Ab ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...